Petition27 Mar 2020 11:10
Address handed over to Fimea, THL, STM and Chief Physicians2020-03-27 10:56:16
The address has been released with 2753 signatures. I sent the following bulletin to the media. Thanks to everyone for participating, it's great that awareness of the potential of this drug has spread! One idea to keep up with it would be a Facebook group, Let's think over the weekend ... Have a good weekend,
Mrs. Aarne Koutaniemi
Address for Intensive Care Medication delivered to Hospital District Chiefs, Fimea, THL and the Ministry of Social Affairs and Health; over 2,700 Finnish signatories (8 days from 19 March to 27 March 2020)
https://www.adressit.com/lupa_koronaviruksen_tehohoitolaake_traumakinelle
Quotes from signatories (more than 100 in public comment):
- "Help Finland and the world cope with this pandemic." - Hannele Ranta, Siilinjärvi
- “It is absolutely necessary to take this medicine when no other medicine is available. This is a readily available medicine in Finland. ” - Roni Korkeaniemi, Kauhava
- "This medicine can really save the life of your loved one." - Sari Mäki, Kaarina
- “If the threat of death is real and the situation is critical, I do not understand why the drug should not be used when the patient so wishes. I understand the drug has already been tested in humans. ” - Henriika Maunula, Turku
There has been news lately and this week about a Finnish drug, Traumaquine, which would be suitable for the treatment of pneumonia or respiratory failure syndrome in intensive care patients. The purpose of the address is to rush to consider and apply for special permits for the use of the drug. There is a potential for a significant reduction in coronavirus deaths and for ensuring the adequacy of intensive care capacity.
On Wednesday, March 25, Fimea, the Center for Pharmaceutical Safety and Development, stated that no one has yet applied for a special permit for the use of Traumakine. In Finland, the use of unlicensed medicinal products is possible in clinical trials or with the special permission of Fimea. A special permit may be granted if no other treatment is available or the desired result is not achieved by other treatment. Authorization for the use of the medicinal product is sought by the donor, usually a pharmacy or a hospital pharmacy. The authorization may apply to an individual patient or to a specific healthcare unit, such as a hospital. The attending physician is always responsible for the treatment he prescribes, and this responsibility is emphasized when prescribing unlicensed medicines.
Will Traumakine be released in time for special permits to alleviate the coronary crisis?